We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LMB:NASDAQLimbach Holdings, Inc. Analysis

Data as of 2026-06-22 - not real-time

$80.15

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Limbach Holdings (LMB) is trading at $80.15, just above its 20‑day SMA of $79.14 but still below the 50‑day ($83.75) and 200‑day ($85.16) averages, indicating a short‑term bounce within a longer‑term bearish backdrop. The RSI sits at 49.8, suggesting neutral momentum, while the MACD histogram is positive and the MACD line sits above its signal, hinting at a modest upside catalyst. Volatility is elevated at nearly 60% over the past 30 days and the stock’s beta exceeds 1.3, underscoring heightened sensitivity to market swings. On the fundamentals side, revenue grew modestly 4.3% YoY to $652 M, but margins remain thin (gross 25%, operating Analyst consensus is bullish (Buy) with a mean target of $116.6, driven by a low forward PE of 15.9 and strong ROE (~19%).
Despite the bullish analyst outlook, the combination of high leverage, shrinking volume, and pronounced price volatility suggests caution. The stock sits between a support level of $70.5 and resistance near $85.8, leaving limited upside unless it can break the resistance and sustain higher volumes. Investors should weigh the upside potential against the valuation disconnect and sector cyclicality before committing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price hovering between support and resistance
  • bearish longer‑term trend despite short‑term MACD bullishness
  • decreasing trading volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • low forward PE relative to peers
  • positive free cash flow and solid ROE
  • analyst consensus and target price upside

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • significant valuation gap between market price and DCF fair value
  • high debt burden and sector cyclicality
  • sustained earnings growth potential

Key Metrics & Analysis

Financial Health

Revenue Growth4.30%
Profit Margin5.09%
P/E Ratio29.3
ROE18.59%
ROA7.78%
Debt/Equity38.95
P/B Ratio4.9
Op. Cash Flow$35.6M
Free Cash Flow$18.6M
Industry P/E31.4

Technical Analysis

TrendBearish
RSI49.8
Support$70.51
Resistance$85.79
MA 20$79.14
MA 50$83.75
MA 200$85.16
MACDBullish
VolumeDecreasing
Fear & Greed Index91.23

Valuation

Fair Value$19.65
Target Price$116.60
Upside/Downside45.48%
GradeOvervalued
TypeBlend

Risk Assessment

Beta1.32
Volatility59.64%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.